• Prestige Consumer Healthcare cut fiscal 2027 revenue guidance to $1.28 billion–$1.29 billion from $1.29 billion–$1.315 billion.
• Adjusted diluted earnings per share are now forecast at $4.48–$4.55, down from $4.55–$4.65.
• Adjusted free cash flow is projected at $265 million or more, versus the previous minimum of $270 million.
• Organic revenue is expected to be approximately flat, versus previous growth guidance of 1%–3%; excluding Clear Eyes, growth should approach 2%.
• Lower second-half Clear Eyes revenue is anticipated versus a year earlier; the earnings outlook reflects reduced revenue expectations and higher interest expense.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prestige Consumer Healthcare Inc. published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.